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Previous studies showed an increased prevalence of human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) thumb subdomain polymorphisms Pro272, Arg277, and Thr286 in patients failing therapy
with nucleoside analogue combinations. Interestingly, wild-type HIV-1BH10 RT contains Pro272, Arg277, and
Thr286. Here, we demonstrate that in the presence of zidovudine, HIV-1BH10 RT mutations P272A/R277K/
T286A produce a significant reduction of the viral replication capacity in peripheral blood mononuclear cells
in both the absence and presence of M41L/T215Y. In studies carried out with recombinant enzymes, we show
that RT thumb subdomain mutations decrease primer-unblocking activity on RNA/DNA complexes, but not on
DNA/DNA template-primers. These effects were observed with primers terminated with thymidine analogues
(i.e., zidovudine and stavudine) and carbovir (the relevant derivative of abacavir) and were more pronounced
when mutations were introduced in the wild-type HIV-1BH10 RT sequence context. RT thumb subdomain
mutations increased by 2-fold the apparent dissociation equilibrium constant (Kd) for RNA/DNA without
affecting the Kd for DNA/DNA substrates. RNase H assays carried out with RNA/DNA complexes did not reveal
an increase in the reaction rate or in secondary cleavage events that could account for the decreased excision
activity. The interaction of Arg277 with the phosphate backbone of the RNA template in HIV-1 RT bound to
RNA/DNA and the location of Thr286 close to the RNA strand are consistent with thumb polymorphisms
playing a role in decreasing nucleoside RT inhibitor excision activity on RNA/DNA template-primers by
affecting interactions with the template-primer duplex without involvement of the RNase H activity of the
enzyme.
Human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) is a major target for antiretroviral drug
development (3, 61). HIV-1 RT catalyzes the conversion of the
viral single-stranded genomic RNA into a double-stranded
DNA that integrates into the host genome. HIV-1 RT is a
heterodimer composed of 66- and 51-kDa subunits, with sub-
domains termed fingers, thumb, palm, and connection in both
subunits and an RNase H domain in the large subunit only (23,
26, 29).
Approved antiretroviral drugs targeting the HIV-1 RT
include nucleoside and nucleotide inhibitors (zidovudine,
lamivudine, stavudine, didanosine, zalcitabine, abacavir,
emtricitabine, and tenofovir) and nonnucleoside inhibitors
(nevirapine, delavirdine, efavirenz, and etravirine) (39). Nu-
cleoside RT inhibitors (NRTIs) mimic natural nucleosides.
Inside the cell, nucleoside (and nucleotide) analogues need
to be phosphorylated to their active triphosphate forms to
act as competitive inhibitors of HIV-1 RT. Since NRTIs lack
a 3-OH group, their incorporation results in chain termi-
nation (12, 38, 62). Despite the efficacy of current antiret-
roviral therapies, the selection and emergence of drug-re-
sistant HIV-1 strains are major factors contributing to
treatment failure.
HIV-1 RT mutations conferring resistance to nucleoside (or
nucleotide) inhibitors act either by (i) improving discrimina-
tion against the RT inhibitors (15, 54, 59) or (ii) by increasing
the RT’s ability to remove 3-terminal chain terminator inhib-
itors from blocked DNA primers, through phosphorolysis me-
diated by ATP or pyrophosphate (PPi) (2, 41). The nucleotide
excision or primer-unblocking mechanism appears to be most
relevant for the acquisition of resistance to thymidine ana-
logues, such as zidovudine (AZT) (3-azido-3-deoxythymi-
dine) and stavudine (d4T) (2,3-didehydro-2,3-dideoxythy-
midine), through the accumulation of the so-called thymidine
analogue resistance mutations (TAMs) (i.e., M41L, D67N,
K70R, L210W, T215F or T215Y, and K219E or K219Q) (for
recent reviews, see references 38 and 68). TAMs increase the
rate of nucleotide excision. Although primer-unblocking effi-
ciencies are influenced by the nucleotide sequence context
(44), available data indicate that thymidine analogues and
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tenofovir are the best substrates of the reaction, while cytidine
analogues are removed very inefficiently (7, 25, 31, 33, 41, 42,
46, 55, 63, 72). Despite being excisable, there is no agreement
on the unblocking efficiencies for primers terminated with car-
bovir monophosphate (CBVMP) (46, 56, 72) or dideoxyade-
nosine monophosphate (ddAMP) (25, 43, 46). CBVMP and
ddAMP are active metabolites of abacavir and didanosine,
respectively.
Computational analysis of the HIV genetic variability in the
RT-coding region revealed an association between the pres-
ence of TAMs and mutations at codons 35, 39, 43, 122, 203,
207, 208, 214, 218, 223, and 228 in patients failing therapy with
RT inhibitors (9, 11, 65). Some of those mutations appear to
increase viral fitness in the presence of TAMs, as demon-
strated for K43E (24), Q207D (30), and L214F (52). However,
very often, genotypic analysis is restricted to RT residues 1 to
240, while growing evidence suggests that potential antiretro-
viral therapy-related mutations in the thumb-connection sub-
domains (codons 241 to 424) and RNase H domains (codons
425 to 560) can likewise contribute to resistance to RT inhib-
itors. Thus, recent reports have suggested that mutations in the
connection subdomain (e.g., E312Q, G335C/D, N348I,
A360I/V, V365I, and A376S) and in the RNase H domain of
the RT (e.g., Q509L, H539N, or D549N) can significantly in-
crease zidovudine resistance by altering the balance between
excision and template RNA degradation (13, 47, 48, 73). A
reduction of the specific RNase H activity of the viral RT
stabilizes the RNA/DNA duplex, giving RT more time to ex-
cise the AZT from the terminated primer (8, 14, 18).
The analysis of HIV-1 subtype B genomes of isolates ob-
tained from untreated patients reveals three major polymor-
phisms within the RT thumb subdomain at positions 272, 277,
and 286 (Stanford University HIV Drug Resistance Database
[http://hivdb.stanford.edu]). Ala and Pro were found at posi-
tion 272 in 47.4% and 44.0% of the sequenced isolates, respec-
tively. At position 277, 59.0% of the sequences contained Lys,
while 40.9% contained Arg. The variability at position 286 was
lower, with Thr and Ala found in 69.1% and 29.0% of the
sequences, respectively. Previous cross-sectional studies car-
ried out with a large database containing HIV-1 subtype B pol
sequences from patients treated in Spanish hospitals revealed
an increased prevalence of Pro272, Arg277, and Thr286 in
isolates from individuals failing therapy with abacavir/d4T and
other nucleoside analogue combinations (20).
The p66 thumb subdomain plays a role in DNA polymeriza-
tion by making important interactions with the minor groove of
the template-primer through -helices H (residues 255 to 268)
and I (residues 278 to 286) (5, 16), while the p51 thumb
subdomain contributes to the stabilization of the p66/p51 het-
erodimer (69). In addition, interactions between the p51
thumb subdomain and the RNase H domain of p66 appear to
be essential for the conversion of the RT heterodimer from an
inactive to an active form (45). Amino acid substitutions
G262A and W266A within -helix H are known to decrease
RT processivity and frameshift fidelity (4) while impairing the
RNase H-mediated removal of the polypurine tract during
reverse transcription (51). These effects suggest that mutations
in the RT thumb subdomain could alter the balance between
excision and template RNA degradation in a way that could be
similar to that reported for resistance-associated connection
subdomain and RNase H domain mutations (13, 18, 47, 48,
73). Here, we show the effects of thumb subdomain polymor-
phisms on viral replication capacity and provide insights into
the mechanism by which Pro272, Arg277, and Thr286 confer a
selective advantage for viral replication in the presence of
excisable nucleotide analogues.
(A preliminary report of this work has been presented at the
International HIV & Hepatitis Virus Drug Resistance Work-
shop & Curative Strategies, at Dubrovnik, Croatia, 8 to 12
June 2010, abstract 66 [5a].)
MATERIALS AND METHODS
Reverse transcriptases. In this study, the HIV-1BH10 RT has been arbitrarily
designated the wild-type (WT) RT, and thumb subdomain polymorphisms have
been considered mutations introduced in the sequence context of the BH10
enzyme (P272A, R277K, and T286A). Expression and purification of WT HIV-
1BH10 RT, MAK_SSSY RT (HIV-1BH10 RT containing a Ser-Ser insertion be-
tween codons 69 and 70 and containing mutations M41L, A62V, T69S, K70R,
and T215Y) and an RNase H-deficient RT (HIV-1 group O RT with mutations
V75I/E478Q) were performed with modified versions of plasmid p66RTB, as
previously described (1, 6, 10, 34, 36). Other mutant RTs were obtained by using
the QuikChange site-directed mutagenesis kit (Stratagene), following the man-
ufacturer’s instructions. The double mutant M41L/T215Y was obtained with
previously described mutagenic primers (10, 35). To introduce the P272A and
R277K mutations, we used primers 5-CAAGTCAGATTTACGCAGGGATTA
AAGTAAAGCAATTATGTAAAC-3 and 5-GTTTACATAATTGCTTTACT
TTAATCCCTGCGTAAATCTGACTTG-3. To introduce the T286A mutation,
the mutagenic primers were 5-CTCCTTAGAGGAGCCAAAGCACTAACAG
A-3 and 5-TCTGTTAGTGCTTTGGCTCCTCTAAGGAG-3. The intro-
duced mutations were confirmed by DNA sequencing. RT p66 subunits carrying
a His6 tag at their C terminus were coexpressed with HIV-1 protease in Esche-
richia coli XL1 Blue to obtain p66/p51 heterodimers, which were later purified by
ionic exchange followed by affinity chromatography (6, 34). RT concentrations
were determined by active site titration as previously described (27).
Nucleotides and template-primers. Stock solutions (100 mM) of deoxynucleo-
side triphosphates (dNTPs), dideoxy-ATP (ddATP), and ATP were obtained
from GE Healthcare. AZT triphosphate (AZTTP), and carbovir triphosphate
(CBVTP) were purchased from Moravek Biochemicals (Brea, CA). Stavudine
triphosphate (d4TTP) was obtained from Sierra Bioresearch (Tucson, AZ).
Before use, nucleoside triphosphates were treated with inorganic pyrophos-
phatase (Roche) to remove traces of PPi (33). DNA oligonucleotides 21P
(5-ATACTTTAACCATATGTATCC-3), 25PGA (5-TGGTAGGGCTATA
CATTCTTGCAGG-3), 31T (5-TTTTTTTTTAGGATACATATGGTTAAAG
TAT-3), D38 (5-GGGTCCTTTCTTACCTGCAAGAATGTATAGCCCT
ACCA-3), D38C (5-GGGTCCTTTATTCCCTGCAAGAATGTATAGCCCT
ACCA-3), D38T (5-GGGTCCTTTCAATCCTGCAAGAATGTATAGCCC
TACCA-3), and PR26 (5-CCTGTTCGGGCGCCACTGCTAGAGAT-3) and
RNA oligonucleotides 31rna (5-GGGUCCUUUCUUACCUGCAAGAAUGU
AUAGC-3), 31Trna (5-UUUUUUUUUAGGAUACAUAUGGUUAAAGU
AU-3), D38rna (5-GGGUCCUUUCUUACCUGCAAGAAUGUAUAGCCC
UACCA-3), D38Crna (5-GGGUCCUUUAUUCCCUGCAAGAAUGUAUA
GCCCUACCA-3), and T35rna (5-AGAAUGGAAAAUCUCUAGCAGUGG
CGCCCGAACAG-3) were obtained from Invitrogen. Oligonucleotides were
labeled at their 5 termini with [-32P]ATP (Perkin Elmer) and T4 polynucle-
otide kinase (Promega), and then annealed to their corresponding templates or
primers depending on the experiment.
Chain terminator excision assays. RT-catalyzed DNA rescue reactions were
performed with D38/25PGA, D38C/25PGA, and D38T/25PGA DNA duplexes,
as previously described (32, 35). Briefly, the phosphorylated template-primer (75
nM) was preincubated at 37°C for 10 min in the presence of the corresponding
RT at an active enzyme concentration of 60 nM in 50 mM HEPES buffer (pH
7.0) containing 15 mM NaCl, 15 mM magnesium acetate, 130 mM potassium
acetate, 1 mM dithiothreitol, and 5% (wt/vol) polyethylene glycol 6000. Reac-
tions were initiated by adding an equal amount of preincubation buffer contain-
ing the NRTI in its triphosphorylated form at a final concentration of 25 M.
After the samples were incubated at 37°C for 30 min, rescue reactions were
initiated by adding a mixture of all dNTPs in the presence of sodium PPi (200
M) or ATP (3.2 mM) depending on the assay. In these assays, all dNTPs except
dATP were supplied at a final concentration of 100 M. Since the next comple-
mentary dNTP (dATP in our assay conditions) has an inhibitory effect on the
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rescue reaction, time course experiments of the unblocking and extension reac-
tions were carried out with 1 M dATP. Rescue reactions were also performed
with the RNA/DNA template-primers D38rna/25PGA and D38Crna/25PGA.
These reactions were carried out under the same conditions as for the DNA
duplexes, but the dNTP and inhibitor concentrations were 2-fold higher. Excision
and extension reactions were carried out after preincubating the corresponding
RT with template-primer and triphosphorylated NRTI for 10 min at 37°C. In
experiments designed to assess the inhibitory effect of dATP, extension reaction
mixtures were incubated for 15 to 40 min in the presence of different concen-
trations of dATP. In all cases, incubation times were within the linear range of
the corresponding time course experiment. The reactions were stopped by add-
ing an equal amount of sample loading buffer (10 mM EDTA in 90% formamide
containing 3 mg/ml xylene cyanol FF and 3 mg/ml bromophenol blue). Products
were resolved on a denaturing 20% (wt/vol) polyacrylamide–8 M urea gel, and
primer rescue was quantified by phosphorimaging with a BAS 1500 scanner
(Fuji) using the program Tina version 2.09 (Raytest Isotopenmessgerate GmbH,
Staubenhardt, Germany).
Pre-steady-state kinetics of the ATP-dependent excision reaction. For these
experiments, primer 25PGA was blocked at its 3 end with d4TTP or CBVTP,
using terminal deoxynucleotidyltransferase as previously described (33). Then,
the free nucleotides were eliminated by repeated passage through a Quick Spin
minicolumn (Roche), until the A260 remained unchanged. Blocked primers were
labeled at their 5 terminus with [-32P]ATP and T4 polynucleotide kinase and
annealed to template D38rna or D38Crna as described above, in order to obtain
the template-primers D38rna/25PGAd4T and D38Crna/25PGACBV. Single-turn-
over conditions were used to study the excision of d4T monophosphate (d4TMP)
and CBVMP. Solutions containing 250 nM RT and 30 nM D38rna/25PGAd4T or
D38Crna/25PGACBV in RT buffer (15 mM HEPES [pH 7.0], 4 mM NaCl, 4 mM
magnesium acetate, 130 mM KCH3COO, 1 mM dithiothreitol, and 5% [wt/vol]
polyethylene glycol) were mixed with equal volumes of RT buffer containing 6.4
mM ATP and 36 mM MgCl2. Excision reactions were carried out for 0 to 60 min
at 37°C. Aliquots were removed after defined incubation periods, quenched with
sample loading buffer, and analyzed by denaturing polyacrylamide gel electro-
phoresis as described above. The formation of product (concentration of product
[P]) over time was fitted to a single exponential decay: [P]  A  ekobs  t,
where kobs is the apparent kinetic constant of the excision reaction. A linear
regression was used to fit the data when the excision rates were low. In those
cases, we assumed that the amount of active RT was identical to the template-
primer concentration in the assay, since reactions were carried out with a large
excess of RT relative to the RNA/DNA duplex.
Determination of dissociation equilibrium constants (Kd) for WT and mutant
RTs and DNA/DNA and RNA/DNA template-primers. RTs were preincubated
with increasing concentrations of the 5-32P-labeled 25/38-mer DNA-DNA (2 to
60 nM) for 10 min at 37°C in 10 l of a buffer containing 100 mM HEPES (pH
7.0), 30 mM NaCl, 30 mM magnesium acetate, 130 mM KCH3COO, 1 mM
dithiothreitol, and 5% (wt/vol) polyethylene glycol. Reactions were initiated by
the addition of 10 l of 1 mM dTTP to 10 l of the solution indicated above, and
incubated at 37°C. In these experiments, the active RT concentration was around
3 nM. Aliquots of 4 l were then removed at 10, 20, 30, and 40 s, quenched with
sample loading buffer, and analyzed by denaturing polyacrylamide gel electro-
phoresis as described above. The burst amplitudes (RT bound to template-
primer at time zero) were plotted as a function of the template-primer concen-
tration, and the data were fitted to a quadratic equation to obtain the equilibrium
dissociation constant for RT binding to template-primer (37).
RNase H assays. RNase H activity was evaluated with 31Trna/21P and
D38rna/25PGA complexes as previously described (1). Assays were carried out at
37°C in 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 5 mM MgCl2, and 50 nM
32P-labeled RNA/DNA template-primer, in the presence of 100 nM RT (active
site concentration). Aliquots were removed at various times, quenched with
equal volumes of gel loading dye, and analyzed by denaturing polyacrylamide gel
electrophoresis as described above. In addition, the RNase H activity of WT and
mutant RTs was determined with an AZT-terminated RNA/DNA substrate (i.e.,
T35rna/PR26) (8). Briefly, the 32P-labeled T35rna/PR26 complex (80 nM) was
blocked at the 3 end of the primer with AZTTP in the presence of a previously
characterized RNase H-deficient RT (HIV-1 group O RT containing mutations
V75I/E478Q [1]). Reaction mixtures were incubated for 60 min at 37°C in 50 mM
Tris-HCl (pH 8.0), 50 mM KCl, 10 mM MgCl2, and 60 M AZTTP in the
presence of 30 nM RT. After heat inactivation of the enzyme, the free AZTTP
was eliminated with a Quick Spin minicolumn (Roche) as described above.
T35rna/PR26AZT RNase H cleavage reactions were carried out at 37°C in 50 mM
Tris-HCl (pH 8.0), 50 mM KCl, and 10 mM MgCl2, containing 0.3 mM ATP, 20
nM 32P-labeled RNA/DNA template-primer and the corresponding RT at a 200
nM active site concentration.
Recombinant virus and drug susceptibility tests. These recombinant virus and
drug susceptibility assays were performed as described previously (32, 36).
Briefly, full-length RT coding sequence DNA was amplified by PCR from the
expression plasmids carrying the appropriate RT, using primers IN3 and IN5
(36). The PCR products were then cotransfected in MT-4 cells with an RT-
deleted HXB2-D clone previously linearized with BstEII (28). Culture superna-
tants were harvested when the HIV-1 p24 antigen concentration surpassed 20
ng/ml. Progeny virus was propagated and titrated in MT-4 cells. The nucleotide
sequence of the RT-coding region of the progeny virus was PCR amplified with
the above-mentioned primers and checked for possible reversions or undesired
mutations. The MT-4 cells and the deleted HXB2-D clone were obtained from
the AIDS Reagent Program (Medical Research Council). RT inhibitors were
obtained from the NIH AIDS Research and Reference Reagent Program. HIV-1
drug susceptibility data were obtained after infecting 30,000 MT-4 cells with 100
50% tissue culture infective doses (TCID50) of virus at a multiplicity of infection
of 0.003 by exposing the HIV-1-infected cultures to various concentrations of
each drug (5-fold dilutions). After the MT-4 cells were allowed to proliferate for
5 days, the number of viable cells was quantified by a tetrazolium-based colori-
metric method [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) method] as described elsewhere (50).
Replication capacity assays. Viral replication kinetics of mutant viruses was
assayed by infecting 5  106 peripheral blood mononuclear cells (PBMCs)
(mixed from two healthy donors), previously stimulated with 3 g/ml of phyto-
hemagglutinin (Sigma-Aldrich) and 10 U/ml of interleukin 2 with 500 TCID50 of
each viral stock (multiplicity of infection of 0.0001) (52). After incubation for 2 h
at 37°C, cells were washed twice with phosphate-buffered saline and resuspended
in RPMI 1640 medium supplemented with 20% fetal bovine serum and inter-
leukin 2 (10 U/ml) at a final concentration of 1 106 cells/ml. Zidovudine (AZT)
at different concentrations was added to the cultures when indicated. Viral
replication was quantified by measuring HIV-1 p24Gag antigen production in the
culture supernatant for 10 days. Growth kinetics was analyzed by fitting a linear
model to the log-transformed p24Gag data during the exponential growth phase
by maximum likelihood methods.
RESULTS
Thumb subdomain polymorphisms and their effects on viral
replication. Our previous statistical analysis carried out with
HIV-1 pol sequences obtained from patients treated in Spain
showed that several RT thumb subdomain polymorphisms
(i.e., Pro272, Arg277, and Thr286) were selected during ther-
apy with nucleoside drug combinations such as d4T/abacavir,
d4T/ddI, ddI/abacavir, d4T/lamivudine, and d4T/tenofovir
(20). The largest levels of statistical significance were observed
with the first two combinations. In addition, correlated pairs of
mutations at positions 272 and 277 and positions 272 and 286
were observed in HIV sequences from patients failing therapy
with d4T and ddI. Despite the statistical correlation, the effects
of thumb mutations P272A/R277K/T286A on nucleoside (or
nucleotide) RT inhibitor susceptibility were not significant in
phenotypic assays (Table 1). All viruses tested were found to
be susceptible to d4T, abacavir, ddI, tenofovir, lamivudine, and
nevirapine. Statistically significant differences between the
50% inhibitory concentrations (IC50s) obtained with WT and
mutant HIV-1 were observed only in the case of AZT (P 
0.01 by Student’s t test). Thus, recombinant HIV-1 containing
RT mutations M41L/T215Y showed a decrease in susceptibil-
ity to AZT of about 3-fold. Interestingly, in the presence of
TAMs (M41L/T215Y), the addition of the thumb subdomain
mutations P272A, R277K, and T286A produced a slight de-
crease of the IC50 for the inhibitor.
Viral replication kinetics assays carried out in PBMCs
showed that mutations P272A/R277K/T286A had a negative
effect on viral fitness (Fig. 1). Growth kinetics curves were
analyzed by fitting a linear model to the log-transformed
p24Gag data during the exponential growth phase (see Fig. S1
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in the supplemental material). The slope of p24 antigen pro-
duction provides a reliable estimate of the viral replication
capacity. As shown in Fig. 1, the addition of thumb subdomain
mutations to HIV variants containing TAMs decreased viral
replication capacity by 11 to 34%. These effects were more
significant at higher concentrations of AZT. A similar trend
was observed when mutations were introduced in a WT re-
combinant virus, although the negative effects were observed
only in experiments carried out in the presence of 0.2 M
AZT. These results together with the observed associations
between thumb subdomain polymorphisms and failure to ther-
apies containing combinations of excisable NRTIs suggested a
link between excision and the selection of HIV-1 variants con-
taining Pro272/Arg277/Thr286.
Effects of mutations on the ATP-mediated excision of NRTIs
from chain-terminated DNA/DNA and RNA/DNA template-
primers. The ability of RTs to unblock NRTI-terminated prim-
ers was initially assessed with DNA/DNA template-primers
(Fig. 2). An excision-proficient RT (i.e., MAK_SSSY [M41L/
A62V/T69SSS/K70R/T215Y]) was used as a reference. In the
presence of 3.2 mM ATP, MAK_SSSY was able to excise AZT
monophosphate (AZTMP), d4TMP, CBVMP, and ddAMP,
although ddAMP was removed at a very low rate. The ATP-
dependent phosphorolytic activities of WT and mutant RTs
(M41L/T215Y, M41L/T215Y/P272A/R277K/T286A, and
P272A/R277K/T286A) were rather small in comparison with
the activity shown by the MAK_SSSY RT. Although M41L/
T215Y and M41L/T215Y/P272A/R277K/T286A RTs showed
some activity with AZTMP-, d4TMP- and CBVMP-terminated
primers, thumb subdomain mutations had a minor effect on
excision. As previously observed with other RT variants, all
enzymes tested showed similar excision efficiencies in the pres-
ence of PPi (200 M) (data not shown).
As in the case of DNA/DNA template-primers, the effi-
ciency of the ATP-dependent phosphorolytic activity on RNA/
DNA substrates in reactions catalyzed by MAK_SSSY RT
followed the order AZTMP 	 d4TMP 	 CBVMP (Fig. 3).
Control experiments carried out with d4T-terminated duplexes
showed that the efficiencies of the unblocking and extension
reactions catalyzed by all RTs were similar in the presence of
30 nM RT and 10 nM D38rna/25PGA (Fig. 3) to the efficien-
cies obtained in the presence of 24 nM RT and 30 nM D38rna/
25PGA (data not shown). The ATP-mediated excision activity
of M41L/T215Y and M41L/T215Y/P272A/R277K/T286A RTs
was higher in reactions carried out with blocked RNA/DNA
template-primers than with DNA/DNA substrates. Although
both enzymes had remarkable excision activity, mutations
P272A, R277K, and T286A produced a small reduction in the
corresponding excision rates. These differences could not be
attributed to their susceptibility to inhibition by the next com-
plementary dNTP (see Table S1 in the supplemental material).
Thus, in reactions catalyzed by M41L/T215Y and M41L/
T215Y/P272A/R277K/T286A RTs, ATP-dependent rescue of
primers terminated with d4TMP was inhibited by the next
complementary dNTP at concentrations of around 4 M.
These values were similar to those reported for other RTs and
obtained in reactions carried out with different DNA/DNA
template-primers (10, 36, 42).
Interestingly, the introduction of P272A/R277K/T286A in
an otherwise WT sequence context rendered an enzyme lack-
ing ATP-dependent phosphorolytic activity in our assay con-
ditions. These effects were observed in the presence of RNA/
DNA duplexes containing primers terminated with AZTMP,
TABLE 1. Susceptibility of HIV-1 constructs to RT inhibitors
RT
IC50 (nM)a
AZT d4T Abacavir ddI Tenofovir Lamivudine Nevirapine
WT 5.1 
 2.6 315.6 
 44.9 1,280.8 
 242.4 2,210.4 
 363.6 181.0 
 38.6 1,014.1 
 39.3 44.0 
 15.7
P272A/R277K/
T286A
6.1 
 2.3 (1.2) 289.3 
 50.9 (0.9) 1,169.8 
 112.1 (0.9) 2,499.8 
 894.9 (1.1) 221.1 
 28.5 (1.2) 1,519.2 
 486.0 (1.5) 23.1 
 4.1 (0.5)
M41L/T215Y 14.5 
 0.8 (2.8) 399.2 
 54.3 (1.3) 1,526.1 
 236.7 (1.2) 1,888.8 
 604.0 (0.9) 264.4 
 38.5 (1.5) 1,988.7 
 628.1 (1.9) 22.8 
 14.4 (0.5)
M41L/T215Y/
P272A/R277K/
T286A
10.7 
 6.5 (2.1) 378.6 
 90.3 (1.2) 1,768.2 
 188.1 (1.4) 2,562.4 
 710.3 (1.2) 261.4 
 78.3 (1.4) 1,558.8 
 854.2 (1.5) 29.1 
 24.2 (0.7)
a The IC50 values shown are averages 
 standard deviations of at least three tests, with each one performed six times. The fold increase in IC50 relative to the
wild-type HXB2 virus control carrying the RT sequence of BH10 is shown in parentheses.
FIG. 1. Replication kinetics assay in the absence and presence of
AZT. The slope of p24 antigen production of each virus after infection
of PBMCs (mixed from two donors) is shown by the bars. Comparisons
of WT versus mutant P272A/R277K/T286A virus and mutant M41L/
T215Y virus versus M41L/T215Y/P272A/R277K/T286A virus are
shown in panels A and B, respectively. The significance of the differ-
ence between slopes was calculated using the GraphPrism v. 4 software
(, P 0.05; , P 0.01). Solid black circles represent the percentage
loss of replication capacity of the recombinant HIV-1 variants contain-
ing the P272A, R277K, and T286A mutations in the absence (A) or
presence (B) of M41L/T215Y mutations under different assay condi-
tions.
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d4TMP, or CBVMP. The presence of Pro272, Arg277, and
Thr286 (as in the WT BH10 RT) conferred detectable excision
activity, particularly on primers terminated with AZT and d4T,
annealed to RNA templates (Fig. 3).
The d4TMP excision rates for WT and mutant P272A/
R277K/T286A RT were determined under single-turnover
conditions by using a d4TMP-terminated primer previously
annealed to a 38-nucleotide RNA template in the presence of
FIG. 2. ATP-mediated excision of AZTMP, d4TMP, CBVMP, and ddAMP from DNA/DNA template-primers by WT and mutant RTs. Reactions
were carried out with 38/25-mer DNA/DNA heteropolymeric complexes (sequences shown at the top of the figure). First, the inhibitor was incorporated
at position 1 (indicated with an asterisk) of the 25-nucleotide primer (lane P) to generate a 26-nucleotide product (lane B). Excision of the inhibitor
and further primer extension in the presence of 3.2 mM ATP and a mixture of dNTPs lead to the formation of a fully extended 38-nucleotide product.
A representative time course experiment of a primer rescue reaction is shown in lanes 1 to 9, which correspond to aliquots removed 2, 4, 6, 8, 10, 12, 15,
20, and 30 min after the addition of 3.2 mM ATP (gel in the top right corner of the figure). Graphs of time course experiments of primer rescue reactions
initiated from inhibitor-terminated primers are given below. All dNTPs in the assays were supplied at 100 M, except for dATP whose concentration was
1 M. Template-primer and active RT concentrations in these assays were 30 and 24 nM, respectively. The values (averages
 standard deviations [error
bars]) were obtained from three independent experiments. The MAK_SSSY RT is an excision-proficient enzyme that contains a Ser-Ser insertion
between codons 69 and 70 and contains mutations M41L, A62V, T69S, K70R, and T215Y.
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3.2 mM ATP but without dNTPs. The WT RT showed a
d4TMP excision rate (kobs) of 0.0032 min
1, which was about
2.5 times higher than the value obtained for mutant P272A/
R277K/T286A RT (Fig. 4). Both enzymes showed negligible
activity on CBVMP-terminated RNA/DNA substrates. The
differences between M41L/T215Y and M41L/T215Y/P272A/
R277K/T286A RTs were not significant in these assays. Both
enzymes showed remarkable d4TMP excision activity on RNA/
DNA templates (kobs around 0.08 min
1), although they were
less efficient in removing CBVMP (kobs around 0.0036 min
1).
RNase H activity of WT and mutant RTs. Thumb subdomain
polymorphisms did not have a major impact on the RNase H
activity as measured with the 31Trna/21P complex (Fig. 5A).
Cleavage patterns monitored on the 5-end-labeled RNA tem-
plate revealed similar kinetics for reactions catalyzed by RTs
with or without thumb subdomain mutations. No secondary
cleavages were detected with the 31Trna/21P template-primer,
under our assay conditions. Similar results were obtained with
RNA/DNA template-primers used in rescue reactions (i.e.,
D38rna/25PGA) (Fig. 5A), although in this case the primary
cleavage at position 18 occurred with higher efficiency. An
increased frequency of secondary RNase H cleavages could
diminish RNA/DNA duplex length and decrease the efficiency
of NRTI excision. RNase H secondary cleavages occurring
during the excision reaction were monitored with an AZT-
terminated RNA/DNA complex in the presence of ATP. Cat-
alytic rate constants for the cleavage of D38rna and 31Trna
were in the range of 0.97 to 1.67 min1 and 0.49 to 0.71 min1,
respectively (Fig. 5B). Differences between WT and P272A/
R277K/T286A RTs and between M41L/T215Y and M41L/
T215Y/P272A/R277K/T286A RTs were not significant in these
assays (P 	 0.1 by Student’s t test). As shown in Fig. 5C and in
Fig. S2 in the supplemental material, in an excision-competent
mode, mutant RTs with P272A/R277K/T286A, M41L/T215Y,
and M41L/T215Y/P272A/R277K/T286A had similar kinetics
of formation of the 10 cleavage product. However, the WT
enzyme showed 1.6-fold increased activity. Similar band pat-
terns were observed for all tested RTs when the reactions were
carried out in the absence of ATP (data not shown). As dem-
onstrated for several RT connection and RNase H domain
mutations (8, 48, 53), increased RNase H secondary cleavage
efficiency correlates with lower levels of excision activity.
Therefore, the higher ATP-mediated excision activity of WT
RT relative to mutant P272A/R277K/T286A cannot be ex-
plained by invoking the effects of thumb subdomain mutations
on polymerase-independent cleavages.
Effects of thumb subdomain polymorphisms on template-
primer binding. The effects of thumb subdomain mutations on
substrate binding were determined by measuring the equilib-
rium dissociation constants (Kd) for WT and mutant RTs and
DNA/DNA and RNA/DNA template-primers. Both template-
primers were substrates of the excision reactions shown in Fig.
2 and 3. However, the RNA/DNA template-primer used (i.e.,
31rna/25PGA) was a derivative of D38rna/25PGA lacking 7
FIG. 3. ATP-mediated excision of AZTMP, d4TMP, and CBVMP from RNA/DNA template-primers by WT and mutant RTs. Time course
experiments of excision reactions were carried out in the presence of 3.2 mM ATP. Template-primers used are indicated below. All dNTPs in the
assays were supplied at 200 M, except for dATP whose concentration was 2 M. Template-primer and active RT concentrations in these assays
were 10 and 30 nM, respectively. The values (averages 
 standard deviations [error bars]) were obtained from three independent experiments.
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nucleotides at the 3 end of the RNA. These nucleotides were
eliminated, since the corresponding RNase H primary cleavage
(at position 18) occurs early during the ATP-mediated exci-
sion reaction (Fig. 5). As shown in Table 2, thumb subdomain
polymorphisms had a minor impact on the Kd for DNA/DNA
complexes (38/25-mer), with values around 2 to 3 nM. How-
ever, WT and mutant M41L/T215Y showed about 2-fold-
higher affinity for RNA/DNA than their homologous counter-
parts having the thumb subdomain mutations P272A, R277K,
and T286A. Primer extension assays carried out with 31rna/
25PGA were consistent with the Kd measurements (Fig. 6). At
low concentrations of template-primer (i.e., 1 nM), the amount
of fully extended product was about 2-fold higher for mutant
M41L/T215Y RT than for M41L/T215Y/P272A/R277K/
T286A RT, while at higher concentrations (i.e., 10 nM), dif-
ferences in the efficiency of the primer extension reaction were
very small. On the other hand, thumb subdomain mutations
had a relatively minor influence on RNase H cleavage patterns
and kinetics in reactions carried out in the presence of low
concentrations of RNA/DNA duplexes (i.e., 1.5 nM D38rna/
25PGA) (see Fig. S3 in the supplemental material). Interest-
ingly, the results of the primer extension assays were in agree-
ment with fitness assays showing that in the absence of
antiretroviral drugs, HIV clones containing the M41L/T215Y
RT had a higher replication capacity than their homologous
HIV-1 variants containing RT mutations M41L/T215Y/P272A/
R277K/T286A (Fig. 1).
DISCUSSION
The HIV-1 RT thumb subdomain residues 255 to 286 form
a characteristic helix-turn-helix secondary structure (termed
the helix clamp) that exhibits sequence homology with other
nucleic acid polymerases (22). In p66, the two -helices (H and
I) interact with the template-primer, while in p51 they play a
structural role by contributing to the stabilization of the RT
heterodimer (23, 29, 40, 69). Our previous statistical analysis
carried out with HIV-1 pol sequences obtained from patients
treated in Spain showed that thumb subdomain polymor-
phisms were selected during therapy with NRTIs (20). In most
cases, polymorphisms were associated with TAMs and the
most significant associations were detected with samples from
patients failing therapy with combinations of excisable NRTIs
(e.g., abacavir/d4T, d4T/ddI, etc.). In those studies, the fre-
quencies of Pro272, Arg277, and Thr286 in the naïve popula-
tion were 45.0%, 25.7%, and 54.5%, respectively. However,
those numbers increase up to 82.6%, 63.0%, and 91.3%, re-
spectively, among isolates from patients failing therapy with
abacavir/d4T (20).
Phenotypic assays carried out with mutant RTs bearing
thumb subdomain mutations like P272A, R277K, and T286A
failed to detect differences in their susceptibility to NRTIs.
This result was not unexpected, assuming their accessory role
in resistance and the fact that assays were carried out in MT-4
cells. These cells contain high concentrations of dNTP that are
known to counteract nucleotide excision mechanisms of resis-
tance, particularly for abacavir, d4T, ddI, and tenofovir (64,
67). However, in phenotypic assays, mutant HIV-1 carrying the
M41L/T215Y/P272A/R277K/T286A RT was found to be
slightly more susceptible to AZT than its homologous coun-
terpart containing the double mutant M41L/T215Y polymer-
ase. Moreover, viral replication capacity assays carried out with
PBMCs underlined these differences and showed that HIV-1
clones bearing Pro272, Arg277, and Thr286 in their RT-coding
region had an increased growth rate in the presence of AZT. A
phylogenetic tree obtained with the HIV-1 pol sequences de-
rived from our previously reported cross-sectional study (20)
showed the clustering of isolates obtained from patients failing
therapy with abacavir and d4T bearing Pro272, Arg277, and
Thr286 in their RT-coding region (Fig. 7). Despite the lack of
sequence information from the connection and RNase H do-
mains of the RT, these data argue in favor of the selection of
FIG. 4. Kinetics of the ATP-dependent excision of d4TMP and
CBVMP from RNA/DNA template-primers. Time course experiments
for the excision reaction of d4TMP- or CBVMP-terminated primers
(26-mers) annealed to their corresponding 38-nucleotide RNA tem-
plates (30 nM) were determined in the presence of 3.2 mM ATP. The
excision reaction was catalyzed by WT and mutant RTs (250 nM). The
calculated kobs values for the d4TMP excision reaction were 0.0032 

0.0003 min1 for WT RT, 0.0014 
 0.0002 min1 for mutant P272A/
R277K/T286A RT, 0.0810 
 0.0025 min1 for mutant M41L/T215Y
RT, 0.0782 
 0.0044 min1 for mutant M41L/T215Y/P272A/R277K/
T286A RT, and 0.153 
 0.018 min1 for the MAK_SSSY RT. For the
excision of CBVMP, the kobs values for mutants M41L/T215Y, M41L/
T215Y/P272A/R277K/T286A, and MAK_SSSY RTs were 0.0038 

0.0003 min1, 0.0035 
 0.0002 min1, and 0.0629 
 0.0138 min1,
respectively.
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HIV variants containing specific combinations of RT thumb poly-
morphisms after extensive treatment with excisable NRTIs.
Biochemical analyses designed to elucidate the mechanism
by which thumb subdomain mutations impair viral fitness in
the presence of RT inhibitors support a relevant role for ATP-
mediated excision, particularly for thymidine analogues. Al-
though thumb subdomain mutations did not affect the effi-
ciency of the rescue reactions carried out with chain-
terminated DNA/DNA template-primers, we detected
significant differences in rescue reactions carried out with
RNA/DNA complexes, particularly when mutations were in-
troduced in a WT sequence context. The effects were larger
with AZT- and d4T-terminated primers than with primers
blocked with CBVMP. The rates of excision reactions carried
out in the absence of dNTPs revealed a direct effect of the
mutations in the kinetics of thymidine analogue removal in the
absence of TAMs.
Our results suggest that nucleoside analogue resistance
mechanisms similar to those reported for several connection
subdomain and RNase H domain mutations could operate in
the case of thumb polymorphisms. Thus, several mutations
such as N348I (14, 18, 21, 53, 73), A360V (18, 47) and Q509L
(8) were shown to increase chain-terminated primer rescue
with RNA/DNA complexes, but not with DNA/DNA tem-
plate-primers. However, these mutations as well as others
found in the connection and RNase H domains of the RT (e.g.,
RNase H primer grip mutations such as G335C/D, V365I,
A376S, etc.) (13, 14) had an impact on RNase H activity either
by decreasing its specific activity or by altering the RNase H
FIG. 5. RNase H activity of WT and mutant RTs. (A) [32P]RNA/DNA substrates (50 nM) were cleaved at 37°C in the presence of the
corresponding RT at 100 nM (active enzyme concentration). The template-primer sequences are shown below. For 31Trna/21P, the time points
were obtained after incubating the samples for 1, 2, 4, and 8 min. For D38rna/25PGA, the time points were obtained after incubating the samples
for 10, 20, 30, and 40 s. The time is shown above the gel by the height of the triangle above four lanes for each sample. Mutant RTs are abbreviated
as follows: AKA, P272A/R277K/T286A; LY, M41L/T215Y; LYAKA, M41L/T215Y/P272A/R277K/T286A. An RNase H-deficient RT [RNase H(-)
RT] (HIV-1 group O RT with mutations V75I/E478Q [1]) was included as a control. (B) Time courses of RNase H cleavage reactions carried out
with 31Trna/21P (left), and apparent rate constants for the cleavage of templates 31Trna and D38rna, as obtained from 3 or 4 independent
experiments (right). (C) Representative autoradiogram of the RNase H cleavage activity of WT and mutant RTs during ATP-mediated AZTMP
excision. Assays were performed with the template-primer shown below (at 20 nM) in the presence of 200 nM RT. The time points in the
experiments were 10, 20, 30, 45, 60, 90, 120, 150, and 180 min and are given by the height of the triangle above nine lanes for each sample.
respectively. Cleavage sites are indicated by the black arrows. The labeled 5 ends of the templates are marked with asterisks.
TABLE 2. Dissociation equilibrium constants for WT and mutant
HIV-1 RTs and DNA/DNA and RNA/DNA template-primersa
RT
Apparent Kd (nM)
DNA/DNA RNA/DNA
WT 2.19 
 0.34 1.23 
 0.33
P272A/R277K/T286A 1.75 
 0.44 2.76 
 0.45
M41L/T215Y 3.13 
 0.04 1.14 
 0.30
M41L/T215Y/P272A/R277K/T286A 2.77 
 0.31 2.09 
 0.46
a The Kd values for DNA/DNA binding were obtained with the template-
primer D38/25PGA. The RNA/DNA template-primer used in these experiments
was D31rna/25PGA (sequences given below).
D31rna 5 GGGUCCUUUCUUACCUGCAAGAAUGUAUAGC 3
25PGA 3 GGACGTTCTTACATATCGGGATGGT 5
The values reported are averages 
 standard deviations obtained from three
independent experiments.
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secondary cleavage kinetics. These effects were demonstrated
in the presence of TAMs. We tested the effects of thumb
subdomain polymorphisms on the kinetics of accumulation of
RNase H cleavage fragments, using three different RNA/DNA
complexes and different assay conditions. However, none of
the experiments revealed significant differences between RTs
containing or lacking thumb subdomain mutations. The
G333D mutation in the connection subdomain has also been
found to promote resistance to AZT in the presence of TAMs
without affecting RNase H activity (74), but unlike in the case
of the thumb mutations, an increased excision was reported for
both RNA/DNA and DNA/DNA substrates.
In agreement with the results of rescue assays, we found that
the apparent Kd for DNA/DNA was not influenced by the
presence of thumb polymorphisms. However, in the case of
RNA/DNA substrates, WT and M41L/T215Y RTs showed
higher affinity for the template-primer than their homologous
enzymes having thumb subdomain mutations. These differ-
ences could explain the lower efficiency of rescue reactions
catalyzed by enzymes containing mutations P272A/R277K/
T286A. It should be noted that when the amino acid substitu-
tions M41L and T215Y were present, the negative effect of
P272A/R277K/T286A on the efficiency of the rescue reaction
was barely detectable at template-primer concentrations
around 10 nM but become more significant at lower RNA/
DNA concentrations (i.e., at 1 nM, as shown in Fig. 6). A
reduction in template-primer affinity could influence nucleo-
tide excision by decreasing the availability of NRTI in an ex-
cision-competent conformation but could also decrease the
efficiency of the primer extension reaction after removal of the
chain-terminating inhibitor. In the absence of M41L and
T215Y, thumb subdomain polymorphisms could also affect the
orientation of the blocked primer, thereby influencing excision
by altering the geometry required for the attack of the PPi
donor on the terminal phosphodiester bond.
Our results raise the question of how thumb subdomain
mutations could affect NRTI excision. The analysis of the crys-
tal structure of HIV-1 RT complexed with an RNA/DNA sub-
strate (60) revealed that Arg277 and Thr286 of the p66 subunit
are close to the RNA template strand (Fig. 8). The distances
between an oxygen substituent of the phosphate group linking
template nucleotides 7 and 8 and the amino groups of
Arg277 are around 3.3 Å, while the side chain of Thr286 points
toward the RNA template. A distance of 4.4 Å is observed
between the hydroxyl group of Thr286 and the 2OH of the
ribose at position 8 of the template. On the other hand,
Pro272 is away from the template-primer and could play a role
in facilitating the appropriate folding of the thumb subdomain.
However, single amino acid substitutions at this position were
shown to affect template-primer binding and RT processivity
FIG. 6. Extension of an unblocked DNA primer 25PGA by mutant RTs M41L/T215Y and M41L/T215Y/P272A/R277K/T286A in the presence
of an RNA template (31rna). Reactions were carried out with template-primer concentrations of 1 nM (left panel) and 10 nM (right panel) in 50
mM HEPES buffer (pH 7.0) containing 15 mM NaCl, 15 mM magnesium acetate, 130 mM potassium acetate, 1 mM dithiothreitol, 5% (wt/vol)
polyethylene glycol 6000, and 200 M each dNTP except dATP, which was supplied at 2 M. The RT concentration used in these assays was 3
nM (active site concentration). P, primer; F, full-length product.
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(70). In p51, the relevant thumb subdomain polymorphisms do
not appear to be involved in interactions with the template-
primer, although structural information is still limited. Thr286
could play a role in stabilizing the RT heterodimer (40).
Compared with the HIV-1 RT structure containing RNA/
DNA, the analysis of crystal structures containing DNA/DNA
duplexes (16, 23) revealed that there were less extensive con-
tacts between the RT template grip residues (i.e., -helix I
[residues 278 to 286]) and the DNA/DNA template-primer.
Furthermore, in these two structures, the side chain of Arg277
points away from the DNA/DNA substrate, although Thr286
appears in a similar position as in the structure containing
RNA/DNA, but closer to the sugar-phosphate backbone at
positions 8 and 9 of the template (interatomic distances of
3.7 to 5.4 Å). Similar conformations were observed in the
structures of HIV-1 RT with pre- and posttranslocation
AZTMP-terminated DNA/DNA (58). Taken together, struc-
tural data are consistent with our findings regarding the loss of
affinity for RNA/DNA complexes of mutant RTs containing
R277K and other amino acid substitutions in the polymerase
thumb subdomain. Interestingly, another mutation in -helix I
of the thumb subdomain (i.e., R284K) has been found to be
associated with the accumulation of TAMs in treated patients
(9, 71). Arg284 lies close to the RNA template, and as in the
case of the thumb polymorphisms described in our study, could
affect NRTI excision by altering interactions with the template-
primer. Despite the compelling evidence in favor of excision as
the molecular mechanism facilitating the selection of thumb
polymorphisms under treatment with NRTIs, we cannot ex-
clude the potential contribution of polymorphisms to RT het-
erodimer stability in vivo, either by changing interactions be-
tween p66 and p51 (40, 45, 69) or by altering the susceptibility
of RT subunits to cleavage by the viral protease (17, 49).
In summary, our studies provide strong evidence for a mech-
anism that involves RNase H-independent contributions to
increases in the efficiency of NRTI excision, and in turn, a
selective advantage to these drugs; as well as for the effects of
thumb subdomain polymorphisms Pro272, Arg277, and Thr286
on RNA/DNA template-primer affinity that may result in a
selective advantage both in the presence or in the absence of
RT inhibitors. Although the contribution of thumb subdomain
FIG. 7. Evolutionary relationships of HIV-1 protease and RT-cod-
ing sequences of isolates from naïve patients and individuals failing
therapy with abacavir and d4T. Sequences (GenBank accession num-
bers HM460345 to HM460497) from isolates obtained from patients
failing treatment with abacavir and d4T and from untreated patients
(20) are represented by solid black circles and open circles, respec-
tively. The WT BH10 sequence, encoding Pro272, Arg277 and Thr286
in the viral RT, is represented by the open square. Clusters of isolates
from patients failing therapy with abacavir/d4T are boxed. The evolu-
tionary history was inferred by the neighbor-joining method (57) by
using p-distances in the substitution model. The bootstrap consensus
tree was inferred from 2,000 replicates (19). Branches corresponding
to partitions reproduced in less than 50% bootstrap replicates are
collapsed. The percentages of replicate trees in which the associated
taxa clustered together in the bootstrap test (2,000 replicates) are
shown next to the branches (19). The tree is drawn to scale, with
branch lengths in the same units as those of the evolutionary distances
used to infer the phylogenetic tree. A total of 778 positions were
considered in the final data set (all positions containing gaps and
missing data were eliminated prior to analysis). Phylogenetic trees
were obtained by using MEGA4 software (66).
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polymorphisms to drug resistance may not be significant, their
effects on viral fitness can be relevant for the selection of
NRTI-resistant HIV variants. In this context, accessory muta-
tions in the connection and RNase H domains of the RT could
also modulate the effects of thumb subdomain polymorphisms,
arguing in favor of the inclusion of C-terminal portions of RT
in clinical genotypic and phenotypic assays. Further studies on
the role of accessory mutations should be helpful for designing
prediction algorithms for the viral replication capacity.
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